225 related articles for article (PubMed ID: 33452660)
21. Hydroxychloroquine in systemic lupus erythematosus (SLE).
Ponticelli C; Moroni G
Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
[TBL] [Abstract][Full Text] [Related]
22. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
Hosokawa Y; Oiwa H
Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
[TBL] [Abstract][Full Text] [Related]
23. Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort.
Walbi IA; Albarqi HA; Alghanim NS; Albadi MA; Al Maimouni HM; Alkahtani SA; Alshabi AM; Alali AS; Alqahtani F; Al-Najjar AH; Hazzazi MA; Alanazi DS; Sabei AA; Alsaweed OS; Alajra RK; Alqhtani H
J Int Med Res; 2022 Apr; 50(4):3000605221090363. PubMed ID: 35387504
[TBL] [Abstract][Full Text] [Related]
24. Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.
Chen C; Pan K; Wu B; Li X; Chen Z; Xu Q; Li X; Lv Q
Eur J Clin Pharmacol; 2021 Jan; 77(1):13-24. PubMed ID: 32780229
[TBL] [Abstract][Full Text] [Related]
25. Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis.
Zang Y; Han X; He M; Shi J; Li Y
Naunyn Schmiedebergs Arch Pharmacol; 2021 Apr; 394(4):775-782. PubMed ID: 32892293
[TBL] [Abstract][Full Text] [Related]
26. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
[TBL] [Abstract][Full Text] [Related]
27. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
[TBL] [Abstract][Full Text] [Related]
28. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature.
Nord JE; Shah PK; Rinaldi RZ; Weisman MH
Semin Arthritis Rheum; 2004 Apr; 33(5):336-51. PubMed ID: 15079764
[TBL] [Abstract][Full Text] [Related]
29. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
[TBL] [Abstract][Full Text] [Related]
30. Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic.
Romani S; Gérard A; Fresse A; Viard D; Van-Obberghen É; Micallef J; Rocher F; Drici MD;
Clin Transl Sci; 2021 Jan; 14(1):163-169. PubMed ID: 32964653
[TBL] [Abstract][Full Text] [Related]
31. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study.
Jung SY; Kim MS; Kim MC; Choi SH; Chung JW; Choi ST
Clin Microbiol Infect; 2021 Apr; 27(4):611-617. PubMed ID: 33316402
[TBL] [Abstract][Full Text] [Related]
32. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.
Falcão F; Viegas E; Carmo I; Soares J; Falcao M; Solano M; Cavaco P; Mendes D; Rijo J; Povoa P; Pais Martins A; Carmo E; Mansinho K; Fonseca C; Campos L; Carvalho A; Mirco A; Farinha H; Aldir I; Correia J
Eur J Hosp Pharm; 2021 Sep; 28(5):248-253. PubMed ID: 33452110
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
[TBL] [Abstract][Full Text] [Related]
34. Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials.
Maraolo AE; Grossi A
Immun Inflamm Dis; 2021 Mar; 9(1):31-36. PubMed ID: 33244901
[TBL] [Abstract][Full Text] [Related]
35. Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
Mallhi TH; Ahmad A; Butt MH; Misbah S; Khan YH; Alotaibi NH
J Coll Physicians Surg Pak; 2020 Oct; 30(10):124-128. PubMed ID: 33115586
[TBL] [Abstract][Full Text] [Related]
36. Hydroxychloroquine cardiotoxicity: a case-control study comparing patients with COVID-19 and patients with systemic lupus erythematosus.
Mancuso S; Spinelli FR; Agati L; Ciardi MR; Garufi C; Natalucci F; Molteni E; Truglia S; Riccieri V; Priori R; Mastroianni CM; Conti F
Clin Exp Rheumatol; 2022 May; 40(5):890-896. PubMed ID: 35383554
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic.
Junqueira DR; Rowe BH
Br J Clin Pharmacol; 2021 Apr; 87(4):1758-1767. PubMed ID: 33047848
[TBL] [Abstract][Full Text] [Related]
38. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.
Infante M; Ricordi C; Alejandro R; Caprio M; Fabbri A
Expert Rev Anti Infect Ther; 2021 Jan; 19(1):5-16. PubMed ID: 32693652
[TBL] [Abstract][Full Text] [Related]
39. Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials.
Chi G; Memar Montazerin S; Lee JJ; Kazmi SHA; Shojaei F; Fitzgerald C; Gibson CM
J Med Virol; 2021 Dec; 93(12):6737-6749. PubMed ID: 34370328
[TBL] [Abstract][Full Text] [Related]
40. COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.
Raza HA; Tariq J; Agarwal V; Gupta L
Rheumatol Int; 2021 Feb; 41(2):257-273. PubMed ID: 33386447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
